Orzan et al. [152] identified that these distinctive TP53 mutations in recurrent tumours were detectable at a lower rate in the matched primary tumours, indicating that these GSC populations already existed, but were expanded under therapeutic pressure induced by TMZ. This evidence concerns the gene TP53 and neoplasm.